AZ and Daiichi’s TROP2 ADC shows promise in first-line lung cancer Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate DS-1062, Share X AZ and Daiichi’s TROP2 ADC shows promise in first-line lung cancer https://pharmaphorum.com/news/az-and-daiichis-trop2-adc-shows-promise-in-first-line-lung-cancer/
Merck swings back into Alzheimer’s with $1.1bn Cerevance alliance Merck & Co’s earlier efforts to find new therapies for Alzheimer’s disease resulted in failure, but the company Share X Merck swings back into Alzheimer’s with $1.1bn Cerevance alliance https://pharmaphorum.com/news/merck-swings-back-into-alzheimers-with-1-1bn-cerevance-alliance/
Sanofi pauses enrolment in ex-US tolebrutinib trials Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although Share X Sanofi pauses enrolment in ex-US tolebrutinib trials https://pharmaphorum.com/news/sanofi-pauses-enrolment-in-ex-us-tolebrutinib-trials/
Verona cues up filings for COPD drug after it aces phase 3 test UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary Share X Verona cues up filings for COPD drug after it aces phase 3 test https://pharmaphorum.com/news/verona-cues-up-filings-for-copd-drug-after-it-aces-phase-3-test/
Tagrisso paired with Hutchmed drug clears lung cancer test EGFR inhibitors like AstraZeneca’s Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of Share X Tagrisso paired with Hutchmed drug clears lung cancer test https://pharmaphorum.com/news/tagrisso-paired-with-hutchmed-drug-clears-lung-cancer-test/
Sosei Heptares banks $30m milestone in Neurocrine Bio alliance Sosei Heptares has taken another of its partnered G protein-coupled receptor (GPCR) programmes into mid-stage clinical trials, earning Share X Sosei Heptares banks $30m milestone in Neurocrine Bio alliance https://pharmaphorum.com/news/sosei-heptares-banks-30m-milestone-in-neurocrine-bio-alliance/
Gilead snaps up MiroBio and its checkpoint agonists for $405m Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a Share X Gilead snaps up MiroBio and its checkpoint agonists for $405m https://pharmaphorum.com/news/gilead-snaps-up-mirobio-and-its-checkpoint-agonists-for-405m/
Amgen splashes out on ChemoCentryx and its blockbuster hopeful Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in Share X Amgen splashes out on ChemoCentryx and its blockbuster hopeful https://pharmaphorum.com/news/amgen-splashes-out-on-chemocentryx-and-its-blockbuster-hopeful/
Pfizer takes pipeline blow as it abandons cardiomyopathy drug Pfizer has stopped development of a drug to treat cardiomyopathy caused by a rare form of heart disease, Share X Pfizer takes pipeline blow as it abandons cardiomyopathy drug https://pharmaphorum.com/news/pfizer-takes-pipeline-blow-as-it-abandons-cardiomyopathy-drug/
Keytruda fluffs its lines in prostate, liver cancer trials Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver Share X Keytruda fluffs its lines in prostate, liver cancer trials https://pharmaphorum.com/news/keytruda-fluffs-its-lines-in-prostate-liver-cancer-trials/
Roche adds to pipeline with Poseida, Kiniksa deals Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline Share X Roche adds to pipeline with Poseida, Kiniksa deals https://pharmaphorum.com/news/roche-adds-to-pipeline-with-poseida-kiniksa-deals/
Chinese biotech Sironax raises $200m for RIPK1 pipeline Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire Share X Chinese biotech Sironax raises $200m for RIPK1 pipeline https://pharmaphorum.com/news/chinese-biotech-sironax-raises-200m-for-ripk1-pipeline/
Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a Share X Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde https://pharmaphorum.com/news/phase-3-lung-cancer-fail-dents-prospects-of-ipsen-serviers-onivyde/
AC Immune tries to resurrect crenezumab with new data delve In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab – missed the Share X AC Immune tries to resurrect crenezumab with new data delve https://pharmaphorum.com/news/ac-immune-tries-to-resurrect-crenezumab-with-new-data-delve/
Roche scores phase 3 win for subcutaneous Tecentriq, eyes filings Roche’s Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous Share X Roche scores phase 3 win for subcutaneous Tecentriq, eyes filings https://pharmaphorum.com/news/roche-scores-phase-3-win-for-subcutaneous-tecentriq-eyes-filings/
AbbVie taps Sosei Heptares GPCR expertise with $1.2bn+ alliance Sosei Heptares has signed up a string of big pharma collaborators over the last few years, and one Share X AbbVie taps Sosei Heptares GPCR expertise with $1.2bn+ alliance https://pharmaphorum.com/news/abbvie-taps-sosei-heptares-gpcr-expertise-with-1-2bn-alliance/
Ipsen makes TCR play, grabbing two I-O therapies from Marengo Ipsen has joined the ranks of companies working on T cell receptor (TCR) therapies for cancer, paying $45 Share X Ipsen makes TCR play, grabbing two I-O therapies from Marengo https://pharmaphorum.com/news/ipsen-makes-tcr-play-grabbing-two-i-o-therapies-from-marengo/
AZ, Innate’s checkpoint inhibitor monalizumab flunks phase 3 test AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer, Share X AZ, Innate’s checkpoint inhibitor monalizumab flunks phase 3 test https://pharmaphorum.com/news/az-innates-checkpoint-inhibitor-monalizumab-flunks-phase-3-test/
